Autoantibodies against T-cell costimulatory molecules are produced in canine autoimmune diseases

Journal of Immunotherapy

Volumn 26, Issue 1, 2003, Pages 12-20

  Khatlani, Tanvir S ^a   Ma, Zhiyong ^a   Okuda, Masaru ^a   Inokuma, Hisashi ^a   Onishi, Takafumi ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Autoantibodies; B7 1; CD28; CTLA 4; T cell costimulation

Indexed keywords

AUTOANTIBODY; CD28 ANTIBODY; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYTIC ANEMIA; IMMUNOBLOTTING; MALE; NONHUMAN; PEMPHIGUS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOBLOTTING; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; MALE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROBABILITY; RANDOM ALLOCATION; RECOMBINANT PROTEINS; REFERENCE VALUES;

EID: 0037222565     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200301000-00002     Document Type: Article

References (38)

1. Schwartz RH. Costimulation of T-lymphocytes. The role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
2. Weiss A. Structure and function of the T-cell antigen receptor. J Clin Invest 1990;86:1015-22.
3. Allen PM, Unanue ER. Antigen processing and presentation at the molecular level. Adv Exp Biol 1987;225:147-54.
4. Schwartz RH. A cell culture model of clonal anergy. Science 1990; 248:1349-56.
5. Linsley PS, Greene JL, Tan P, et al. Co-expression and functional cooperativity of CTLA-4 and CD28 on activated T-lymphocytes. J Exp Med 1992;176:1595-1604.
6. Hansen JA, Martin PJ, Nowinski RC. Monoclonal antibodies identifying a novel T-cell antigen and a Ia antigens of human lymphocytes. Immunogenetics 1980;10:247-60.
7. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 1991;174:561-9.
8. Karandikar NJ, Vanderlugt CL, Walunas TL, et al. CTLA-4: a negative regulator of autoimmune diseases. J Exp Med 1996;184:783-8.
9. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T-cell activation. Immunity 1994;1:405-14.
10. Tivol EA, Schweitzer AN, Sharpe AH. Costimualtion and autoimmunity. Curr Opin Immunol 1996;9:396-404.
11. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 Leeds to massive lymphoproliferation and fatal multoorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-47.
12. Denfield RW, Kind P, Sontheimer RD, et al. In situ expression of B7 and CD28 receptor families in skin leisions of patients with lupus erythematosus. Arthritis Rheum 1997;40:814-21.
13. Lüdher F, Hoglund P, Allison JP, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998;187:427-32.
14. Yanagawa T, Hidaka Y, Guimaraes V, et al. CTLA-4 gene polymorphism associated with Grave's disease in a Caucasian population. J Clin Endocrinol Metab 1995;80:41-5.
15. Donner H, Rau H, Walfish PJ, et al. CTLA-4 alanine-17 confers genetic susceptibility to Grave's disease and to type 1 Diabetes Mellitus. J Clin Endocrinol Metab 1997;82:143-6.
16. Anderson DE, Sharpe AH, Hafler DA. The B7-1-CD28/CTLA-4 costimulatory pathways in autoimmune disease of central nervous system. Curr Opin Immunol 1999;11:677-83.
17. Osman C, Swaak AJG. Lymphocytoxic antibodies in SLE: a review of the literature. Clin Rheum 1994;13:21-7.
18. Swaak AJG. Lymphocytotoxic antibodies. In: Autoantibodies. J.B. Peter, Y. Shoenfeld, eds. Amsterdam: Elsevier Science, 1996:478.
19. Winfield JB, Mimura T. Pathogenetic significance of antilymphocyte antibodies with systemic lupus erythematosus. Clin Immunol Immunopathol 1992;63:13-6.
20. Winfield JB, Winchester RJ, Kunkel HG. Association of cold reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus. Arthritis Rheumatol 1975;18:587-94.
21. Morimoto C, Steinberg AD, Letvin NL, et al. Defect of immunoregulatory T-cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J Clin Invest 1987;79: 762-8.
22. + cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:398-405.
23. Wernet P, Kunkel HG. Antibodies to specific surface antigen of T-cells in human sera inhibiting mixed leukocyte culture reactions. J Exp Med 1973;138:1021-6.
24. Sakane T, Steinberg AD, Reeves JP, et al. Studies on immune functions of patients with systemic lupus erythematosus: T-cell subsets and antibodies to T-cell subsets. J Clin Invest 1979;64: 1260-9.
25. Takeuchi TT, Abe M, Kiyota T, et al. In vitro immune response of SLE lymphocytes; the mechanism involved in B-cell activation. Scand J Immunol 1982;16:369-77.
26. Mimura T, Fernsten P, Jarjour W, et al. Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus. J Exp Med 1990;172:653-6.
27. Czyzyk J, Fernsten P, Shaw M, et al. Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1996;39:592-9.
28. Revillard JP, Vincent C, Rivera S. Anti β2-microglobulin lymphocytotoxic autoantibodies in systemic lupus erythematosus. J Immunol 1979;122:614-8.
29. Propper DJ, Lehney WA, Urbaniak SJ, et al. Lymphocytotoxins in sera from highly sensitized multiparous dialysis patients: antibody class, relationship with the HLA and with paternal antigens. Clin Sci 1991;80:87-93.
30. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
31. Amelio RD. Clinical Diagnosis of systemic lupus erythematosus. Contr Nephrol 1985;45:181-4.
32. Khatlani TS, Ohno K, Ma Z, et al. Cloning and sequencing of dog cDNA encoding the T-cell costimulatory molecule (CTLA-4). Immunogenetics 2000;51:79-81.
33. Khatlani TS, Ma Z, Okuda M, et al. Molecular cloning and sequencing of canine T-cell costimulatory molecule (CD28). Vet Immunol Immunopathol 2001;78:341-8.
34. Takashi Y, Ishii CK, Maekawa T, et al. Increase the solubility of foreign proteins in E. coli by co-production of bacterial thioredoxin. J Biol Chem 1995;43:25328-31.
35. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-8.
36. Perrin PJ, Maldonado JH, Davis TA, et al. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157:1333-6.
37. Hurwitz AA, Sullivan TJ, Krummel MF, et al. Specific blockade of CTLA-4/B7-1 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 1997;73:57-62.
38. Perez VL, Van PL, Biuckians A, et al. Induction of peripheral T-cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6:411-7.